PT-141 — Published Research

← Back to PT-141 product page

Melanocortin Receptor Agonism and Central Nervous System Mechanisms

A foundational 2003 review published in Current Topics in Medicinal Chemistry examined PT-141 as a melanocortin receptor agonist acting through central nervous system pathways. The authors described how PT-141, a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), functions as an agonist at melanocortin receptors MC3R and MC4R. The review documented preclinical evidence showing that administration of PT-141 to rats and nonhuman primates resulted in measurable physiological responses mediated through these receptor pathways.

The paper detailed the structure-activity relationships that distinguish PT-141 from its parent compound Melanotan II, noting that PT-141 represents a metabolite of MT-II with a linear rather than fully cyclic structure at one terminus. The authors discussed the pharmacological significance of central melanocortin receptor activation versus peripheral mechanisms, positioning PT-141 as a novel research tool for understanding melanocortin signaling in the CNS.

Citation: King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Current Topics in Medicinal Chemistry. 2003;3(8):845-851. doi:10.2174/1568026033452203. PubMed PMID: 12851303

Pharmacokinetic Profiling and Dose-Response Characterization

A 2004 double-blind, placebo-controlled study published in the International Journal of Impotence Research evaluated the safety, pharmacokinetic properties, and pharmacodynamic effects of intranasal PT-141 administration. The study enrolled healthy males and assessed multiple dose levels ranging from 0.5 to 20 mg. Pharmacokinetic analysis revealed rapid absorption following intranasal administration, with median time to maximum concentration (T_max) of 0.50 hours and mean half-life (t_1/2) ranging from 1.85 to 2.09 hours.

The researchers characterized a clear dose-response relationship, with statistically significant physiological responses observed at doses greater than 7 mg compared to placebo. The pharmacokinetic profile demonstrated linear dose-proportional increases in exposure (C_max and AUC), supporting systematic dose-response modeling. The authors concluded that intranasal PT-141 demonstrated a favorable pharmacokinetic profile suitable for further investigation.

Citation: Diamond LE, Earle DC, Rosen RC, Willets MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901139. PubMed PMID: 14963471

Melanocortin Receptor Signaling and Physiological Response Pathways

A 2006 study published in the Journal of Sexual Medicine investigated the effects of bremelanotide (PT-141) on subjective response measures in a controlled research setting. The investigation specifically examined the compound’s interaction with melanocortin receptors MC3R and MC4R and their downstream signaling pathways. The study utilized validated assessment instruments to quantify physiological and subjective responses following PT-141 administration.

The results demonstrated that PT-141 produced measurable effects through a mechanism distinct from peripheral vasodilatory pathways, confirming a central melanocortin-mediated mechanism of action. The investigators documented that the compound’s effects were temporally correlated with its pharmacokinetic profile, with onset of measurable responses occurring within the expected window based on absorption kinetics. These findings contributed to the understanding of melanocortin receptor signaling in regulating complex physiological processes.

Citation: Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x. PubMed PMID: 16839319

Melanocortins and Receptor Pharmacology: Comprehensive Review

A 2007 review published in Current Topics in Medicinal Chemistry provided a comprehensive examination of melanocortins, including PT-141, in the context of melanocortin receptor pharmacology. The authors surveyed the evidence from animal models demonstrating that melanocortin receptor agonists, including the synthetic analogs MT-II and PT-141, produce measurable physiological effects via central nervous system melanocortin pathways. The review discussed the relative selectivity profiles of various melanocortin agonists at MC1R through MC5R subtypes.

The paper highlighted that bremelanotide’s mechanism of action through melanocortin receptors represented a fundamentally different pharmacological approach compared to peripherally-acting compounds. The authors noted that in animal models, melanocortin receptor activation produced effects that were blocked by melanocortin receptor antagonists (such as SHU9119), confirming receptor specificity. The review positioned PT-141 within the broader context of melanocortin peptide research and receptor pharmacology.

Citation: Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007;7(11):1137-1144. doi:10.2174/156802607780906681. PubMed PMID: 17584134

Melanocortin Receptors and Melanotropic Peptides: Research Perspectives

A 2009 review published in the Annals of the New York Academy of Sciences examined the broader research landscape of melanocortin receptors and melanotropic peptides, with detailed discussion of PT-141 and related compounds. The authors traced the research history from the discovery of α-MSH’s pigmentation effects through the development of superpotent synthetic analogs including MT-II and its metabolite PT-141. The review catalogued the five melanocortin receptor subtypes (MC1R-MC5R) and their tissue distribution, noting that MC3R and MC4R are predominantly expressed in the central nervous system.

The review discussed preclinical evidence from multiple animal models demonstrating that melanocortin receptor agonists produce dose-dependent physiological effects, and that these effects are mediated specifically through central melanocortin receptors rather than peripheral mechanisms. The authors summarized structure-activity relationship studies that informed the design of PT-141 and highlighted the compound’s role as a pharmacological tool for understanding melanocortin receptor biology in the central nervous system.

Citation: Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. PubMed PMID: 16412534

Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.